HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amazon's Solimo Supplements' Prices, Selection Slow Market Share Incursion

This article was originally published in The Rose Sheet

Executive Summary

Amazon’s Solimo supplements and personal care line overall is priced higher than Walgreens' brand but lower than CVS', Jefferies Equity Research Americas found. Solimo could present a formidable threat to the supplements category, but its limited assortment so far and pricing should prevent “material market share shifts” in the near-term, Jefferies says.

You may also be interested in...



‘Late, But Not Too Late’ For OTC Industry To Join The Digital Health Revolution

Speaking during a recent webinar, IQVIA Consumer Health's Andy Tisman gave consumer health firms three pieces of sage advice to help them seize the opportunity offered by digitalization. 

Consumer E-commerce Comfort Helps Amazon Health Product Sales Jump 50%

Amazon’s nutrition and wellness sales soared 55% in 2018 to around $2.5bn and health product sales, including OTC drugs, jumped 50% to about $600m, as consumers grow more comfortable purchasing health products online, says e-commerce market research firm Edge by Ascential.

Amazon Supplements, OTC Drugs Ride Lower Prices To Gains In Market Share

Amazon’s Solimo supplement and Basic Care OTC lines unlikely to expand much, says Jefferies analyst Brian Tanquilut. Still, brands are well positioned against retail private label competitors, as most products are priced lower than similar products by Walgreens and CVS.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS121719

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel